Innate Killer Summit Europe | 18-20th October | London

Memo

The momentum of innate immune cell R&D is growing exponentially to harness innate immune responses in oncology, realise scaled allogeneic manufacturing, and drive commercial stage-products. Now is the time to gather this burgeoning community at the crucible of innovation: in Europe. The Innate Killer Summit Europe gathers the founders of the field to overcome the technical challenges of developing Gamma Delta T, NK, and Macrophage therapies. Gain a comprehensive overview of candidates to inform strategic development and bring you up to speed on the latest innovations in the innate immunity. Bridging the gap between the technicalities of early discovery through to process optimisation and leaping regulatory hurdles, this is the must-attend meeting to accelerate safe and scalable therapies in Europe. Join with your team to: Elucidate the mechanism of action for effective tumour targeting to inform future combination strategy - with Bayer, Affimed & Lava TherapeuticsOvercome manufacturing and logistical challenges to supercharge clinical development in Europe - with IN8bio, Glycostem & TakedaNavigate regulatory and reimbursement hurdles to accelerate market access - with Evren Alici (Karolinska Institute), Gadeta & Arovella Join 80+ key European innate immune-based therapy developers in October to chase the holy grail of efficacious, off-the-shelf, solid tumor immunotherapies through innate cell targeting and engineering. Seize your chance to network with innate immune trailblazers from the likes of Sanofi, Takeda, The Karolinska Institute, Glycostem and Bayer to inform your pipeline development and progress the field together with an industry brain trust. Tickets https://go.evvnt.com/1158671-2?pid=5569Brochure https://go.evvnt.com/1158671-3?pid=5569 Prices:Conference + Workshop Day - Pharma & Biotech Drug Developer Pricing - On the Door GBP 3246.00Conference + 1 Workshop - Pharma & Biotech Drug Developer Pricing - On the Door GBP 2548.00Conference Only - Pharma & Biotech Drug Developer Pricing - On the Door GBP 2199.00Conference + Workshop Day - Academic Pricing - On the Door GBP 2546.00Conference + 1 Workshop - Academic Pricing - On the Door GBP 2048.00Conference Only - Academic Pricing - On the Door GBP 1799.00Conference + Workshop Day - Standard Pricing - On the Door GBP 4046.00Conference Only - Standard Pricing - On the Door GBP 2699.00 Speakers: Joachim Koch VP of Translational Biology Affimed, Michael Baker CEO Arovella, Katharina Filarsky Head of Assays 3 in Biologics Research Bayer AG, Ioana Panait Researcher Beacon Targeted Therapeutics, Sharon Longhurst VP of Development Gadeta, Aviad Pato Head of NK Research Gamida Cell, Kai Pinkernell CMO Glycostem Therapeutics B.V., Volker Huppert CDO Glycostem Therapeutics B.V., Mark Lowdell CSO INmune Bio, Inc., Kate Rochlin COO IN8bio, Robert Igarashi Head of Discovery & Pre-Clinical Development Kiadis, a Sanofi Company, Evren Alici Group Leader, Associate Professor Karolinska Institutet, Michael Uhlin Professor, Head of Development & IT, Department of Clinical Immunology Karolinska Institutet & Karolinska University Hospital, Niklas Björkström Associate Professor, MD PhD Karolinska Institutet, Hans van der Vandervliet CSO Lava Therapeutics, Marc van Dijk CSO MiNK Therapeutics, Donald Shaffer Head of Precision Cytokines & Cell Therapies Sanofi, Michael Leek CEO TC Biopharm, Angela Scott COO & Founder TC Biopharm, Jonathan Fisher Group Leader University College London, Marta Barisa Senior Fellow & Scientific Project Manager University College London, Lulu Chu Associate Director, Cell Therapy Clinical Pharmacology & Modeling Takeda, Namir Hassan CEO Zelluna Immunotherapy AS, Dan Kemp CEO Wugen Dates and Time: Starts: Tue, Oct 18, 2022 ( 8:30 AM) and Ends: Thu, Oct 20, 2022 ( 4:00 PM) Venue details: Hilton London Kensington, 179-199 Holland Park Avenue, London, England, W11 4UL, United Kingdom